These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Genetic landscape of common venous malformations in the head and neck. Du Z; Liu JL; You YH; Wang LZ; He J; Zheng JW; Zhang ZY; Wang YA J Vasc Surg Venous Lymphat Disord; 2021 Jul; 9(4):1007-1016.e7. PubMed ID: 33248299 [TBL] [Abstract][Full Text] [Related]
11. New and Emerging Targeted Therapies for Vascular Malformations. Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381 [TBL] [Abstract][Full Text] [Related]
13. Updates on Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum. Chen H; Gao W; Liu H; Sun B; Hua C; Lin X Ann Plast Surg; 2023 May; 90(5S Suppl 2):S209-S215. PubMed ID: 36729078 [TBL] [Abstract][Full Text] [Related]
14. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans. Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive phenotypic and genomic characterization of venous malformations. Hirose K; Hori Y; Ozeki M; Motooka D; Hata K; Tahara S; Matsui T; Kohara M; Maruyama K; Imanaka-Yoshida K; Toyosawa S; Morii E Hum Pathol; 2024 Mar; 145():48-55. PubMed ID: 38367816 [TBL] [Abstract][Full Text] [Related]
16. Development of Molecular Therapies for Venous Malformations. Kangas J; Nätynki M; Eklund L Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():6-19. PubMed ID: 29668117 [TBL] [Abstract][Full Text] [Related]
17. Neutralization of HSF1 in cells from PIK3CA-related overgrowth spectrum patients blocks abnormal proliferation. Da Costa R; De Almeida S; Chevarin M; Hadj-Rabia S; Leclerc-Mercier S; Thauvin-Robinet C; Garrido C; Faivre L; Vabres P; Duplomb L; Jego G Biochem Biophys Res Commun; 2020 Sep; 530(3):520-526. PubMed ID: 32620236 [TBL] [Abstract][Full Text] [Related]
18. Four-month-old with severe PIK3CA-related overgrowth spectrum disorder successfully treated with alpelisb. Cossio ML; Rodríguez J; Flores JC; De Barbieri F; Flores Á; Marín J; Florin C; Cuevas F; Gutiérrez M Pediatr Dermatol; 2024; 41(4):714-717. PubMed ID: 38444084 [TBL] [Abstract][Full Text] [Related]
19. CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations. Moneghini L; Tosi D; Graziani D; Caretti A; Colletti G; Baraldini V; Cattaneo E; Spaccini L; Zocca A; Bulfamante GP Hum Pathol; 2020 May; 99():98-106. PubMed ID: 32272124 [TBL] [Abstract][Full Text] [Related]
20. PIK3CA vascular overgrowth syndromes: an update. Hughes M; Hao M; Luu M Curr Opin Pediatr; 2020 Aug; 32(4):539-546. PubMed ID: 32692051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]